About reMYND
reMYND is a company based in Leuven (Belgium) founded in 2002.. reMYND has raised $28.17 million across 4 funding rounds from investors including KU Leuven, BNP Paribas Fortis and PMV. The company has 46 employees as of December 31, 2022. reMYND offers products and services including Alzheimer’s Program, Huntington’s Program, and CRO Services. reMYND operates in a competitive market with competitors including Rheonix, Phoremost, 64x Bio, Nanna Therapeutics and Adaptyv Biosystems, among others.
- Headquarter Leuven, Belgium
- Employees 46 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Remynd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$28.17 M (USD)
in 4 rounds
-
Latest Funding Round
$14.57 M (USD), Series B
Jan 22, 2021
-
Investors
KU Leuven
& 7 more
-
Employee Count
46
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of reMYND
reMYND offers a comprehensive portfolio of products and services, including Alzheimer’s Program, Huntington’s Program, and CRO Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Restores synaptic function and reduces pathology in Alzheimer’s disease.
Targets oxidative stress to restore cortico-striatal transmission.
Assesses experimental treatments in proprietary mouse models.
Unlock access to complete
Unlock access to complete
Funding Insights of reMYND
reMYND has successfully raised a total of $28.17M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $14.57 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $14.6M
-
First Round
First Round
(29 Jun 2011)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series B - reMYND | Valuation | SFPI | |
| Dec, 2018 | Amount | Series B - reMYND | Valuation | PMV , Korys | |
| Mar, 2016 | Amount | Grant - reMYND | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in reMYND
reMYND has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include KU Leuven, BNP Paribas Fortis and PMV. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sustainable investing in conscious consumer, energy transition, and healthy living sectors.
|
Founded Year | Domain | Location | |
|
Private equity is directed toward private and public companies.
|
Founded Year | Domain | Location | |
|
Private debt funds are managed across multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by reMYND
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - reMYND
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Remynd Comparisons
Competitors of reMYND
reMYND operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rheonix, Phoremost, 64x Bio, Nanna Therapeutics and Adaptyv Biosystems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Instruments for automated molecular assays are developed using disposable cartridges.
|
|
| domain | founded_year | HQ Location |
Phenotypic screening platform developed to identify drug targets and pathways.
|
|
| domain | founded_year | HQ Location |
Cell and gene therapies for multiple diseases are developed.
|
|
| domain | founded_year | HQ Location |
In-vitro directed evolution platform is provided for drug discovery.
|
|
| domain | founded_year | HQ Location |
Protein design, synthesis, testing, and validation services are offered.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Remynd
Frequently Asked Questions about reMYND
When was reMYND founded?
reMYND was founded in 2002 and raised its 1st funding round 9 years after it was founded.
Where is reMYND located?
reMYND is headquartered in Leuven, Belgium. It is registered at Leuven, Flemish Brabant, Belgium.
Is reMYND a funded company?
reMYND is a funded company, having raised a total of $28.17M across 4 funding rounds to date. The company's 1st funding round was a Grant of $524.81K, raised on Jun 29, 2011.
How many employees does reMYND have?
As of Dec 31, 2022, the latest employee count at reMYND is 46.
What does reMYND do?
reMYND was founded in 2002 in Leuven, Belgium, within the biotechnology sector. In vivo contract research services are offered using proprietary mouse models for progressive amyloidopathy, tauopathy, and combined APP-TAU conditions. A drug discovery program is pursued, emphasizing small molecule therapeutics for protein-misfolding-related neurodegenerative diseases. The lead candidate is advancing through IND-enabling studies for Alzheimers disease, supported by additional programs for Alzheimers, diabetes, Parkinsons, Huntingtons disease, and amyotrophic lateral sclerosis.
Who are the top competitors of reMYND?
What products or services does reMYND offer?
reMYND offers Alzheimer’s Program, Huntington’s Program, and CRO Services.
Who are reMYND's investors?
reMYND has 8 investors. Key investors include KU Leuven, BNP Paribas Fortis, PMV, European Union, and Korys.